{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:16:03Z","timestamp":1767485763002,"version":"3.48.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:00:00Z","timestamp":1765497600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"R01 funding","award":["5R01CA269835-03"],"award-info":[{"award-number":["5R01CA269835-03"]}]},{"name":"R01 funding","award":["5R01CA269835-03"],"award-info":[{"award-number":["5R01CA269835-03"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"DOI":"10.1007\/s00277-025-06539-z","type":"journal-article","created":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T00:14:43Z","timestamp":1765498483000},"page":"6305-6314","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long term outcomes of older patients with classical hodgkin lymphoma: an analysis of the Texas cancer registry"],"prefix":"10.1007","volume":"104","author":[{"given":"Ethan A.","family":"Burns","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hala","family":"Hassanain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunil","family":"Mathur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Darshil","family":"Choksi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cesar Gentille","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-hang Anthony","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanh","family":"Mai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carrie","family":"Yuen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shilpan","family":"Shah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-chi Andrew","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sai Ravi","family":"Pingali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,12]]},"reference":[{"key":"6539_CR1","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1182\/blood-2011-09-378414","volume":"119","author":"AM Evens","year":"2012","unstructured":"Evens AM, Helenowski I, Ramsdale E, Nabhan C, Karmali R, Hanson B et al (2012) A retrospective multicenter analysis of elderly hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood 119:692\u2013695","journal-title":"Blood"},{"key":"6539_CR2","doi-asserted-by":"publisher","first-page":"725219","DOI":"10.1155\/2011\/725219","volume":"2011","author":"P Shenoy","year":"2011","unstructured":"Shenoy P, Maggioncalda A, Malik N, Flowers CR (2011) Incidence patterns and outcomes for hodgkin lymphoma patients in the united States. Adv Hematol 2011:725219","journal-title":"Adv Hematol"},{"issue":"1","key":"6539_CR3","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/hematology.2019000028","volume":"2019","author":"AM Evens","year":"2019","unstructured":"Evens AM, Carter J, Loh KP, David KA (2019) Management of older hodgkin lymphoma patients. Hematol Am Soc Hematol Educ Program 2019(1):233\u2013242","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"6539_CR4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1093\/annonc\/mdh012","volume":"15","author":"A Levis","year":"2004","unstructured":"Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E et al (2004) VEPEMB in elderly hodgkin\u2019s lymphoma patients. Results from an intergruppo Italiano linfomi (IIL) study. Ann Oncol 15:123\u2013128","journal-title":"Ann Oncol"},{"key":"6539_CR5","first-page":"1087","volume":"20","author":"CD Weekes","year":"2002","unstructured":"Weekes CD, Vose JM, Lynch JC, Weisenburger DD, Bierman PJ, Greiner T et al (2002) Hodgkin\u2019s disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen. J Clin Oncol 20:1087\u20131093","journal-title":"J Clin Oncol"},{"key":"6539_CR6","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1200\/JCO.2012.47.3058","volume":"31","author":"AM Evens","year":"2013","unstructured":"Evens AM, Hong F (2013) How can outcomes be improved for older patients with Hodgkin lymphoma? J Clin Oncol 31:1502\u20131505","journal-title":"J Clin Oncol"},{"issue":"1","key":"6539_CR7","doi-asserted-by":"publisher","first-page":"e2014050","DOI":"10.4084\/MJHID.2014.050","volume":"6","author":"A Thyss","year":"2014","unstructured":"Thyss A, Saada E, Gastaud L, Peyrade F, Re D (2014) Hodgkin\u2019s lymphoma in older patients: an orphan disease? Mediterr J Hematol Infect Dis 6(1):e2014050","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"2","key":"6539_CR8","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1046\/j.1365-2141.2002.03815.x","volume":"119","author":"GL Stark","year":"2002","unstructured":"Stark GL, Wood KM, Jack F, Angus B, Proctor SJ, Taylor PR (2002) Hodgkin\u2019s disease in the elderly: a population-based study. Br J Haematol 119(2):432\u2013440","journal-title":"Br J Haematol"},{"issue":"10","key":"6539_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.28373","volume":"4","author":"AM Rodday","year":"2021","unstructured":"Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM (2021) Association of treatment intensity with survival in older patients with hodgkin lymphoma. JAMA Netw Open 4(10):e2128373","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6539_CR10","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1111\/bjh.12222","volume":"161","author":"AM Evens","year":"2013","unstructured":"Evens AM, Hong F, Gordon LI, Fisher RI, Bartlett NL, Connors JM et al (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine, and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. Br J Haematol 161(1):76\u201386","journal-title":"Br J Haematol"},{"issue":"4","key":"6539_CR11","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1056\/NEJMoa1708984","volume":"378","author":"JM Connors","year":"2018","unstructured":"Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, ECHELON-1 Study Group (2018) Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 378(4):331\u2013344","journal-title":"N Engl J Med"},{"key":"6539_CR12","doi-asserted-by":"crossref","unstructured":"Ansell SM, Radford J, Connors JM, D\u0142ugosz-Danecka M, Kim WS, Gallamini A, ECHELON-1 study group et al (2022) Overall survival with Brentuximab Vedotin in stage III or IV Hodgkin\u2019s lymphoma. N Engl J Med 387(4):310\u2013320","DOI":"10.1056\/NEJMoa2206125"},{"key":"6539_CR13","unstructured":"Vincent GK, Velkoff VA (2010) The next four decades, the older population in the United States: 2010 to 2050. Current Population Reports P25-1138. U.S. Census Bureau, Washington, DC"},{"key":"6539_CR14","unstructured":"Texas Demographic Center Demographics of Texas and the aging of the population. Available from: >https:\/\/demographics.texas.gov\/Resources\/Presentations\/OSD\/2018\/2018_02_22_JLLSeniorsHousingOutlook.pdf . Accessed 25 February 2022"},{"issue":"5","key":"6539_CR15","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1007\/s00277-023-05140-6","volume":"102","author":"EA Burns","year":"2023","unstructured":"Burns EA, Sanchez CG, Mathur S, Guerrero C, Muhsen IN, Sarfraz H et al (2023) Long-term outcomes in older patients with primary central nervous system lymphoma: an analysis of the Texas cancer registry. Ann Hematol 102(5):1111\u20131120","journal-title":"Ann Hematol"},{"key":"6539_CR16","unstructured":"Texas Health and Human Services (2022) About the Texas cancer registry. Available from: https:\/\/www.dshs.texas.gov\/tcr\/. Accessed April"},{"key":"6539_CR17","doi-asserted-by":"crossref","unstructured":"Burns EA, Wilson JJ, Mathur S, Kieser R, Gong Z, Hu CA et al (2023) Long-term outcomes in patients with Burkitt lymphoma older than 65 years: an analysis of the Texas Cancer Registry. Ann Hematol (Epub ahead of print.)","DOI":"10.1007\/s00277-023-05328-w"},{"issue":"7","key":"6539_CR18","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1002\/1097-0142(19900401)65:7<1635::AID-CNCR2820650730>3.0.CO;2-M","volume":"65","author":"A Walker","year":"1990","unstructured":"Walker A, Schoenfeld ER, Lowman JT, Mettlin CJ, MacMillan J, Grufferman S (1990) Survival of the older patient compared with the younger patient with Hodgkin\u2019s disease. Influence of histologic type, staging, and treatment. Cancer 65(7):1635\u20131640","journal-title":"Cancer"},{"key":"6539_CR19","doi-asserted-by":"crossref","unstructured":"Engert A, Ballova V, Haverkamp H, Pfistner B, Josting A, D\u00fchmke E, German Hodgkin\u2019s Study Group et al (2005) Hodgkin\u2019s lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin\u2019s Study Group. J Clin Oncol 23(22):5052\u20135060","DOI":"10.1200\/JCO.2005.11.080"},{"issue":"6","key":"6539_CR20","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1182\/blood-2007-10-115493","volume":"111","author":"H Brenner","year":"2008","unstructured":"Brenner H, Gondos A, Pulte D (2008) Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patients. Blood 111(6):2977\u20132983","journal-title":"Blood"},{"issue":"6","key":"6539_CR21","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1309\/NB3947K383DJ0LQ2","volume":"128","author":"TW Kelley","year":"2007","unstructured":"Kelley TW, Pohlman B, Elson P, Hsi ED (2007) The ratio of FOXP3\u2009+\u2009regulatory T cells to granzyme B\u2009+\u2009cytotoxic T\/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 128(6):958\u2013965","journal-title":"Am J Clin Pathol"},{"issue":"4","key":"6539_CR22","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1002\/1097-0142(19920815)70:4<830::AID-CNCR2820700418>3.0.CO;2-X","volume":"70","author":"FL Erdkamp","year":"1992","unstructured":"Erdkamp FL, Breed WP, Bosch LJ, Wijnen JT, Blijham GB (1992) Hodgkin disease in the elderly. A registry-based analysis. Cancer 70(4):830\u2013834","journal-title":"Cancer"},{"issue":"2","key":"6539_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.16525","volume":"190","author":"AM Rodday","year":"2020","unstructured":"Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM et al (2020) First-line treatment in older patients with hodgkin lymphoma: a surveillance, epidemiology, and end results (SEER)-medicare population-based study. Br J Haematol 190(2):222\u2013235","journal-title":"Br J Haematol"},{"issue":"5","key":"6539_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1111\/bjh.18564","volume":"200","author":"H Shah","year":"2023","unstructured":"Shah H, Jang H, Kim S, Halwani AS (2023) A comprehensive SEER registry analysis of elderly patients with classical hodgkin lymphoma based on treatment era and race. Br J Haematol 200(5):579\u2013586","journal-title":"Br J Haematol"},{"issue":"5","key":"6539_CR25","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.3324\/haematol.2021.278438","volume":"107","author":"AM Evens","year":"2021","unstructured":"Evens AM, Connors JM, Younes A, Ansell SM, Kim WS, Radford J et al (2021) Older patients (aged \u226560 years) with previously untreated advanced-stage classical Hodgkin lymphoma: a detailed analysis from the phase III ECHELON-1 study. Haematologica 107(5):1086\u20131094","journal-title":"Haematologica"},{"issue":"30","key":"6539_CR26","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1200\/JCO.2018.79.0139","volume":"36","author":"AM Evens","year":"2018","unstructured":"Evens AM, Advani RH, Helenowski IB, Fanale M, Smith SM, Jovanovic BD et al (2018) Multicenter phase II study of sequential Brentuximab Vedotin and doxorubicin, vinblastine, and dacarbazine chemotherapy for older patients with untreated classical Hodgkin lymphoma. J Clin Oncol 36(30):3015\u20133022","journal-title":"J Clin Oncol"},{"issue":"17suppl","key":"6539_CR27","volume":"41","author":"AF Herrera","year":"2023","unstructured":"Herrera AF, LeBlanc ML, Castellino SM, Li H, Rutherford SC, Evens AM et al (2023) SWOG S1826, a randomized study of nivolumab(N)-AVD versus brentuximab vedotin(BV)-AVD in advanced stage (AS) classic hodgkin lymphoma (HL). J Clin Oncol 41(17suppl):LBA4\u2013LBA4","journal-title":"J Clin Oncol"},{"issue":"24","key":"6539_CR28","doi-asserted-by":"publisher","first-page":"6292","DOI":"10.1182\/blood-2011-07-368167","volume":"118","author":"B B\u00f6ll","year":"2011","unstructured":"B\u00f6ll B, Bredenfeld H, G\u00f6rgen H, Halbsguth T, Eich HT, Soekler M et al (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood 118(24):6292\u20136298","journal-title":"Blood"},{"key":"6539_CR29","doi-asserted-by":"crossref","unstructured":"Fossa A, B\u00f6ll B, Goergen H, Kamper P, Lepp\u00e4 S, Molin D, German Hodgkin Study Group and the Nordic Lymphoma Group (2018) T021 (0147) B-CAP (brentuximab vedotin, cyclophosphamide, doxorubicin and prednisone) in older patients with advanced-stage Hodgkin lymphoma: results of a phase II intergroup trial by the German Hodgkin Study Group (GHSG) and the Nordic Lymphoma Group (NLG). Hemasphere 27","DOI":"10.1097\/01.HS9.0000547915.39178.53"},{"issue":"7\u20138","key":"6539_CR30","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1080\/028418602321028283","volume":"41","author":"G Enblad","year":"2002","unstructured":"Enblad G, Gustavsson A, Sundstrom C, Glimelius B (2002) Patients above sixty years of age with hodgkin\u2019s lymphoma treated with a new strategy. Acta Oncol 41(7\u20138):659\u2013667","journal-title":"Acta Oncol"},{"issue":"1","key":"6539_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1093\/annonc\/mdi023","volume":"16","author":"V Ballova","year":"2005","unstructured":"Ballova V, R\u00fcffer JU, Haverkamp H, Pfistner B, M\u00fcller-Hermelink HK, D\u00fchmke E, Worst P, Wilhelmy M, Naumann R, Hentrich M, Eich HT, Josting A, L\u00f6ffler M, Diehl V, Engert A (2005) A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin\u2019s disease comparing BEACOPP baseline and COPP-ABVD (study HD9elderly). Ann Oncol 16(1):124\u2013131","journal-title":"Ann Oncol"},{"issue":"1","key":"6539_CR32","first-page":"46","volume":"79","author":"A Levis","year":"1994","unstructured":"Levis A, Depaoli L, Urgesi A, Bertini M, Orsucci L, Vitolo U, Buchi G, Gallamini A, Gavarotti P, Novarino A, Rota Scalabrini D, Mazza U, Pileri A, Sannazzari GL, Resegotti L (1994) Probability of cure in elderly hodgkin\u2019s disease patients. Haematologica 79(1):46\u201354","journal-title":"Haematologica"},{"issue":"4","key":"6539_CR33","first-page":"438","volume":"88","author":"O Landgren","year":"2003","unstructured":"Landgren O, Algernon C, Axdorph U, Nilsson B, Wedelin C, Porwit-MacDonald A et al (2003) Hodgkin\u2019s lymphoma in the elderly with special reference to type and intensity of chemotherapy in relation to prognosis. Haematologica 88(4):438\u2013444","journal-title":"Haematologica"},{"issue":"8","key":"6539_CR34","doi-asserted-by":"publisher","first-page":"2128","DOI":"10.1093\/annonc\/mdr578","volume":"23","author":"AM Evens","year":"2012","unstructured":"Evens AM, Antillon M, Aschebrook-Kilfoy B, Chiu BC (2012) Racial disparities in Hodgkin\u2019s lymphoma: a comprehensive population-based analysis. Ann Oncol 23(8):2128\u20132137","journal-title":"Ann Oncol"},{"key":"6539_CR35","doi-asserted-by":"crossref","unstructured":"Sykorova A, Mocikova H, Lukasova M, Koren J, Stepankova P, Prochazka V, Czech hodgkin\u2019s lymphoma study group et al (2020) Outcome of elderly patients with classical hodgkin\u2019s lymphoma. Leuk Res 90:106311","DOI":"10.1016\/j.leukres.2020.106311"},{"issue":"3","key":"6539_CR36","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.critrevonc.2008.12.007","volume":"71","author":"SJ Proctor","year":"2009","unstructured":"Proctor SJ, Wilkinson J, Sieniawski M (2009) Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Crit Rev Oncol Hematol 71(3):222\u2013232","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6835","key":"6539_CR37","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1136\/bmj.304.6835.1137","volume":"304","author":"AJ Swerdlow","year":"1992","unstructured":"Swerdlow AJ, Douglas AJ, Hudson GV, Hudson BV, Bennett MH, MacLennan KA (1992) Risk of second primary cancers after Hodgkin\u2019s disease by type of treatment: analysis of 2846 patients in the British National lymphoma investigation. BMJ 304(6835):1137\u20131143","journal-title":"BMJ"},{"issue":"2","key":"6539_CR38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1056\/NEJM198801143180203","volume":"318","author":"MA Tucker","year":"1988","unstructured":"Tucker MA, Coleman CN, Cox RS, Varghese A, Rosenberg SA (1988) Risk of second cancers after treatment for Hodgkin\u2019s disease. N Engl J Med 318(2):76\u201381","journal-title":"N Engl J Med"},{"issue":"2","key":"6539_CR39","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1200\/JCO.1994.12.2.312","volume":"12","author":"FE Van Leeuwen","year":"1994","unstructured":"Van Leeuwen FE, Klokman WJ, Hagenbeek A, Noyon R, van den Belt-Dusebout AW, van Kerkhoff EH et al (1994) Second cancer risk following Hodgkin\u2019s disease: a 20-year follow-up study. J Clin Oncol 12(2):312\u2013325","journal-title":"J Clin Oncol"},{"issue":"17","key":"6539_CR40","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1056\/NEJMoa060476","volume":"355","author":"CI Henschke","year":"2006","unstructured":"International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, Libby DM, Pasmantier MW, Smith JP, Miettinen OS (2006) Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355(17):1763\u201371","journal-title":"N Engl J Med"},{"issue":"3","key":"6539_CR41","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1093\/jnci\/djk029","volume":"99","author":"AJ Swerdlow","year":"2007","unstructured":"Swerdlow AJ, Higgins CD, Smith P, Cunningham D, Hancock BW, Horwich A et al (2007) Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 99(3):206\u2013214","journal-title":"J Natl Cancer Inst"},{"issue":"22","key":"6539_CR42","doi-asserted-by":"publisher","first-page":"2326","DOI":"10.1200\/JCO.2018.78.8687","volume":"36","author":"SG Mohile","year":"2018","unstructured":"Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS et al (2018) Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol 36(22):2326\u20132347","journal-title":"J Clin Oncol"},{"issue":"8","key":"6539_CR43","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1200\/JCO-24-01278","volume":"43","author":"P Torka","year":"2025","unstructured":"Torka P, Feldman T, Savage KJ, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Capadona C, Subzwari S, Galasso N, Yang J, Post M, Boardman A, Caron P, David K, Epstein-Peterson Z, Falchi L, Ghione P, Hamlin P, Horwitz SM, Intlekofer AM, Johnson W, Kumar A, Lue J, Noy A, Owens C, Palomba ML, Salles GA, Steiner R, Stuver R, Vardhana S, Yahalom J, Dogan A, Zelenetz AD, Sch\u00f6der H, Moskowitz AJ (2025) Phase II trial of nivolumab plus doxorubicin, vinblastine, Dacarbazine as frontline therapy in older adults with hodgkin lymphoma. J Clin Oncol 43(8):985\u2013993. https:\/\/doi.org\/10.1200\/JCO-24-01278Epub 2024 Dec 11. PMID: 39661923","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"6539_CR44","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1182\/blood-2023-180114","volume":"142","author":"SC Rutherford","year":"2023","unstructured":"Rutherford SC, Li H, Herrera AF, Leblanc M, Ahmed S, Davison KL, Casulo C, Bartlett NL, Tuscano JM, Hess B, Torka P, Kumar P, Jacobs RW, Song JY, Castellino SM, Kahl BS, Leonard JP, Smith SM, Friedberg JW, Evens AM (2023) Nivolumab-AVD is better tolerated and improves progression-free survival compared to BV-AVD in older patients (aged\u2009\u2265\u200960 years) with advanced stage hodgkin lymphoma enrolled on SWOG S1826. Blood 142(Supplement 1):181. https:\/\/doi.org\/10.1182\/blood-2023-180114","journal-title":"Blood"},{"issue":"1","key":"6539_CR45","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1182\/hematology.2023000449","volume":"2023","author":"AM Evens","year":"2023","unstructured":"Evens AM, McKenna M, Tiger YKR, Upshaw JN (2023) Hodgkin lymphoma treatment for older persons in the modern era. Hematol Am Soc Hematol Educ Program 2023(1):483\u2013499. https:\/\/doi.org\/10.1182\/hematology.2023000449","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"11","key":"6539_CR46","doi-asserted-by":"publisher","first-page":"e808","DOI":"10.1016\/S2352-3026(20)30256-8","volume":"7","author":"BD Cheson","year":"2020","unstructured":"Cheson BD, Bartlett NL, LaPlant B, Lee HJ, Advani RJ, Christian B et al (2020) Brentuximab Vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with hodgkin lymphoma (ACCRU): A multicentre, single-arm, phase 2 trial. Lancet Haematol 7(11):e808\u2013e815. https:\/\/doi.org\/10.1016\/S2352-3026(20)30256-8","journal-title":"Lancet Haematol"},{"key":"6539_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115073","volume":"213","author":"C Rossi","year":"2024","unstructured":"Rossi C, Manson G, Marouf A, Cabannes-Hamy A, Nicolas-Virelizier E, Maerevoet M et al (2024) Classic hodgkin lymphoma: the LYSA pragmatic guidelines. Eur J Cancer 213:115073","journal-title":"Eur J Cancer"},{"issue":"26","key":"6539_CR48","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1182\/blood-2015-06-644336","volume":"126","author":"A Forero-Torres","year":"2015","unstructured":"Forero-Torres A, Holkova B, Goldschmidt J, Chen R, Olsen G, Boccia RV et al (2015) Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. Blood 126(26):2798\u20132804","journal-title":"Blood"},{"issue":"4","key":"6539_CR49","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.3109\/10428194.2014.933820","volume":"56","author":"AJ Olszewski","year":"2015","unstructured":"Olszewski AJ, Castillo JJ (2015) Patterns of care and outcomes in elderly patients with classical Hodgkin lymphoma in the United States. Leuk Lymphoma 56(4):1096\u20131102. https:\/\/doi.org\/10.3109\/10428194.2014.933820","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"6539_CR50","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1158\/1055-9965.EPI-20-1381","volume":"30","author":"AM Rodday","year":"2021","unstructured":"Rodday AM, Li Y, Chen L et al (2021) Outcomes of older patients with classical hodgkin lymphoma in the united states: A population-based analysis. Cancer Epidemiol Biomarkers Prev 30(7):1290\u20131298. https:\/\/doi.org\/10.1158\/1055-9965.EPI-20-1381","journal-title":"Cancer Epidemiol Biomarkers Prev"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06539-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06539-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06539-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T00:15:01Z","timestamp":1767485701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06539-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,12]]},"references-count":50,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6539"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06539-z","relation":{},"ISSN":["1432-0584"],"issn-type":[{"type":"electronic","value":"1432-0584"}],"subject":[],"published":{"date-parts":[[2025,12,12]]},"assertion":[{"value":"29 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}